Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
Romain DiamandAlexandre PeltierJean-Baptiste RocheElena LievoreVito LaceteraGiuseppe ChiacchioValerio BeatriciRiccardo MastroianniGiuseppe SimoneOlivier WindischDaniel BenamranAlexandre FourcadeTruong A NguyenGeorges FournierGaëlle FiardGuillaume PloussardThierry RoumeguereSimone AlbisinniPublished in: The Prostate (2023)
The performance of risk classification systems using MRI and MRI-targeted information was less optimistic when tested in a contemporary set of patients. CAPRA score and STAR-CAP classification were the best-performing and should be preferred for treatment decision-making.
Keyphrases
- prostate cancer
- magnetic resonance
- contrast enhanced
- magnetic resonance imaging
- decision making
- machine learning
- deep learning
- end stage renal disease
- ejection fraction
- cancer therapy
- newly diagnosed
- diffusion weighted imaging
- computed tomography
- radical prostatectomy
- peritoneal dialysis
- healthcare
- social media
- patient reported outcomes
- combination therapy
- replacement therapy
- patient reported